Christine E. Brown
Engineered the IL13Rα2 CAR-T cells that produced a complete response in glioblastoma when infused into the brain.
Christine Brown is an immunologist leading CAR-T development for brain tumours. Her 2016 NEJM case of regression of glioblastoma after intraventricular IL13Rα2 CAR-T infusion and subsequent phase 1 trials established locoregional delivery.
| Title | Journal | Year |
|---|---|---|
| Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy | New England Journal of Medicine | 2016 |
| Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial | Nature Medicine | 2024 |
Pages like this
not linked directly; found by shared links- PersonBehnam Badie
Shares City of Hope, Glioma & glioblastoma, CAR-T cell therapy.
- PersonStephen J. Forman
Shares City of Hope, CAR-T cell therapy.
- PersonRenier J. Brentjens
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- InstitutionCity of Hope Orange County
Shares City of Hope, CAR-T cell therapy.
- PersonCrystal L. Mackall
Shares Armoured, logic-gated & next-gen CARs, Glioma & glioblastoma, CAR-T cell therapy.
- IdeaGD2 CAR-T as consolidation in high-risk neuroblastoma
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.
- IdeaDeliver CAR-T cells straight into the fluid around the brain
Shares City of Hope, Glioma & glioblastoma, CAR-T cell therapy.
- TermT-cell exhaustion and CAR-T persistence
Shares Armoured, logic-gated & next-gen CARs, CAR-T cell therapy.